Asia FX muted, dollar fragile as CPI data boosts Sept rate cut bets
LONDON - Spiritus Mundi plc (LSE:SPMU), a Special Purpose Acquisition Company focused on the clinical diagnostics sector, has entered into an amended Heads of Terms to acquire ResteLab and Restalyst, the company announced on Thursday in its interim results statement.
The acquisition, announced on June 3, will constitute a reverse takeover under UK Financial Conduct Authority Listing Rules, according to the press release. The company is actively pursuing the closing of these acquisitions while seeking additional funds to complete the transactions.
For the six months ended March 31, 2025, Spiritus Mundi reported a loss of £333,866, attributed to ongoing administrative expenses required to operate the company and evaluate potential acquisition opportunities. Cash holdings stood at £531 as of March 31.
"Despite the ongoing volatility in capital markets, we remain committed to our strategy," said Zaccheus Peh, Non-Executive Chairman of Spiritus Mundi. The company noted it is receiving support from its creditors, who are predominantly company advisers.
Spiritus Mundi was established to identify and acquire businesses in the clinical diagnostics space and has been listed on the Main Market of the London Stock Exchange (LON:LSEG) since July 2022. The company has evaluated numerous potential opportunities across laboratory diagnostics, testing services, and digital healthcare since its admission to trading.
The company indicated there have been no significant events since the end of the reporting period, according to the interim results statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.